4basebio PLC Stock OTC Markets
Stocks
FBSB.F
GB00BMCLYF79
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 87.4M 116M 102M 95.91M 164M 11.09B 165M 1.15B 445M 5.67B 435M 425M 18.21B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 73.97M 97.94M 85.95M 81.17M 138M 9.39B 139M 971M 376M 4.8B 368M 360M 15.41B | EV / Sales 2026 * |
28.5x | EV / Sales 2027 * | 22.9x |
| Free-Float |
38.75% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Amy Walker
CEO | Chief Executive Officer | 33 | 2026-02-09 |
Daniel Jones
CTO | Chief Tech/Sci/R&D Officer | - | 2025-02-28 |
Scott Lorimer
COO | Chief Operating Officer | - | 2026-03-11 |
| Director | Title | Age | Since |
|---|---|---|---|
Heikki Lanckriet
BRD | Director/Board Member | 48 | 2020-12-21 |
Amy Walker
BRD | Director/Board Member | 33 | 2024-08-07 |
| Chairman | 60 | 2025-07-07 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 116M | |
| +1.26% | +5.03% | +10.89% | +36.56% | 47.97B | |
| -1.69% | +1.48% | +50.57% | +33.71% | 44.5B | |
| +2.56% | +7.34% | +366.69% | +609.24% | 43.93B | |
| +0.24% | +2.85% | +10.67% | +87.77% | 41.03B | |
| -0.62% | -1.11% | +4.65% | +46.13% | 29.85B | |
| -0.28% | +1.07% | +24.58% | +149.55% | 17.27B | |
| +3.37% | +9.21% | +8.32% | - | 15.34B | |
| +1.24% | +0.38% | +28.88% | +47.74% | 15.3B | |
| -2.21% | -4.70% | - | - | 14.82B | |
| Average | -0.18% | +2.35% | +63.16% | +144.38% | 30B | |
| Weighted average by Cap. | +0.13% | +2.86% | +80.14% | +159.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.6M 3.44M 3.02M 2.85M 4.87M 330M 4.9M 34.14M 13.22M 169M 12.93M 12.65M 542M | 5M 6.62M 5.81M 5.49M 9.36M 635M 9.43M 65.66M 25.43M 324M 24.86M 24.32M 1.04B |
| Net income | -18.2M -24.1M -21.15M -19.97M -34.07M -2.31B -34.31M -239M -92.56M -1.18B -90.48M -88.52M -3.79B | - |
| Net Debt | -13.43M -17.78M -15.6M -14.74M -25.14M -1.7B -25.32M -176M -68.31M -871M -66.77M -65.33M -2.8B | 27.1M 35.88M 31.49M 29.74M 50.73M 3.44B 51.09M 356M 138M 1.76B 135M 132M 5.65B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
